11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Study protocol for an efficacy trial of the “PrEP for Health” intervention to increase HIV PrEP use among people who inject drugs

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          HIV incidence has recently increased among people who inject drugs (PWID) across the United States, with outbreaks occurring in states with long-standing syringe service programs (SSPs) including Massachusetts (MA). Antiretroviral pre-exposure prophylaxis (PrEP) is an evidence-based HIV prevention strategy recommended for PWID, but uptake in this marginalized population is extraordinarily low.

          Methods

          We describe the design and procedures for a National Institute on Drug Abuse (NIDA)-funded (R01) randomized controlled trial (RCT) testing the efficacy of “PrEP for Health,” a multicomponent behavioral intervention to increase PrEP uptake, adherence, and persistence among HIV-negative PWID attending SSPs in two areas of the U.S. Northeast that are heavily affected by injection-related HIV transmission. Participants are equally randomized to receive the “PrEP for Health” intervention (involving individually tailored HIV and PrEP education, motivational interviewing, problem-solving skills and planning, and ongoing navigation support) or an enhanced standard of care (eSOC) control condition involving a brief educational video on the utility of PrEP for HIV prevention. Co-primary outcomes are PrEP uptake (using medical/pharmacy records) and adherence (using tenofovir quantification in hair samples); a secondary outcome is PrEP persistence (using medical/pharmacy records) over 12 months. Major assessments occur at baseline, 1-, 3-, 6-, and 12-month follow-up visits. Planned analyses will examine intervention efficacy, specific hypothesized conceptual mediators of the intervention effect (e.g., self-perceived HIV risk; PrEP knowledge, interest in use, motivation, and behavioral skills) and epidemiologically linked moderators (e.g., age; gender; condomless vaginal or anal sex).

          Discussion

          Findings from our extensive preliminary research with the study population revealed that a multicomponent, theory-based intervention targeting PrEP knowledge, motivation, self-efficacy, behavioral skills, and structural barriers to PrEP access is urgently needed for PWID who are at risk of HIV acquisition. We also learned that SSPs represent a highly acceptable service setting for delivering such interventions. In this study, we are evaluating the efficacy of the “PrEP for Health” intervention. If efficacious, findings from our implementation evaluation could help guide its dissemination to diverse SSPs and possibly other community-based settings accessed by this population.

          Trial registration

          ClinicalTrials.gov number NCT04430257, registered June 12, 2020.

          Related collections

          Most cited references56

          • Record: found
          • Abstract: found
          • Article: not found

          Health promotion by social cognitive means.

          This article examines health promotion and disease prevention from the perspective of social cognitive theory. This theory posits a multifaceted causal structure in which self-efficacy beliefs operate together with goals, outcome expectations, and perceived environmental impediments and facilitators in the regulation of human motivation, behavior, and well-being. Belief in one's efficacy to exercise control is a common pathway through which psychosocial influences affect health functioning. This core belief affects each of the basic processes of personal change--whether people even consider changing their health habits, whether they mobilize the motivation and perseverance needed to succeed should they do so, their ability to recover from setbacks and relapses, and how well they maintain the habit changes they have achieved. Human health is a social matter, not just an individual one. A comprehensive approach to health promotion also requires changing the practices of social systems that have widespread effects on human health.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Ending the HIV Epidemic

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

              Antiretroviral pre-exposure prophylaxis reduces sexual transmission of HIV. We assessed whether daily oral use of tenofovir disoproxil fumarate (tenofovir), an antiretroviral, can reduce HIV transmission in injecting drug users. In this randomised, double-blind, placebo-controlled trial, we enrolled volunteers from 17 drug-treatment clinics in Bangkok, Thailand. Participants were eligible if they were aged 20-60 years, were HIV-negative, and reported injecting drugs during the previous year. We randomly assigned participants (1:1; blocks of four) to either tenofovir or placebo using a computer-generated randomisation sequence. Participants chose either daily directly observed treatment or monthly visits and could switch at monthly visits. Participants received monthly HIV testing and individualised risk-reduction and adherence counselling, blood safety assessments every 3 months, and were offered condoms and methadone treatment. The primary efficacy endpoint was HIV infection, analysed by modified intention-to-treat analysis. This trial is registered with ClinicalTrials.gov, number NCT00119106. Between June 9, 2005, and July 22, 2010, we enrolled 2413 participants, assigning 1204 to tenofovir and 1209 to placebo. Two participants had HIV at enrolment and 50 became infected during follow-up: 17 in the tenofovir group (an incidence of 0·35 per 100 person-years) and 33 in the placebo group (0·68 per 100 person-years), indicating a 48·9% reduction in HIV incidence (95% CI 9·6-72·2; p=0·01). The occurrence of serious adverse events was much the same between the two groups (p=0·35). Nausea was more common in participants in the tenofovir group than in the placebo group (p=0·002). In this study, daily oral tenofovir reduced the risk of HIV infection in people who inject drugs. Pre-exposure prophylaxis with tenofovir can now be considered for use as part of an HIV prevention package for people who inject drugs. US Centers for Disease Control and Prevention and the Bangkok Metropolitan Administration. Copyright © 2013 Elsevier Ltd. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                abazzi@health.ucsd.edu
                katie_biello@brown.edu
                Journal
                BMC Public Health
                BMC Public Health
                BMC Public Health
                BioMed Central (London )
                1471-2458
                17 March 2023
                17 March 2023
                2023
                : 23
                : 513
                Affiliations
                [1 ]GRID grid.266100.3, ISNI 0000 0001 2107 4242, Herbert Wertheim School of Public Health, , University of California, ; 9500 Gilman Drive, San Diego, La Jolla, 92093 CA USA
                [2 ]GRID grid.189504.1, ISNI 0000 0004 1936 7558, Department of Community Health Sciences, , Boston University School of Public Health, ; Boston, MA USA
                [3 ]GRID grid.245849.6, ISNI 0000 0004 0457 1396, Fenway Health, ; Boston, MA USA
                [4 ]GRID grid.420474.1, ISNI 0000 0004 0400 1385, Greater Lawrence Family Health Center, ; Lawrence, MA USA
                [5 ]GRID grid.266102.1, ISNI 0000 0001 2297 6811, Department of Family and Community Medicine, , University of California, ; San Francisco, USA
                [6 ]GRID grid.239395.7, ISNI 0000 0000 9011 8547, Beth Israel Deaconess Medical Center, ; Boston, MA USA
                [7 ]GRID grid.19006.3e, ISNI 0000 0000 9632 6718, Department of Epidemiology, Fielding School of Public Health, , University of California, ; Los Angeles, USA
                [8 ]GRID grid.40263.33, ISNI 0000 0004 1936 9094, Departments of Behavioral & Social Sciences and Epidemiology, , Brown University School of Public Health, ; 121 South Main Street, Providence, 02912 RI USA
                [9 ]GRID grid.40263.33, ISNI 0000 0004 1936 9094, Center for Health Promotion and Health Equity, , Brown University, ; Providence, RI USA
                [10 ]GRID grid.266100.3, ISNI 0000 0001 2107 4242, Herbert Wertheim School of Public Health, , University of California, ; 9500 Gilman Drive, MTF 265E (Mail Code 0725), La Jolla, 92161 CA USA
                Article
                15429
                10.1186/s12889-023-15429-w
                10021034
                36932369
                5938d78a-61a0-461d-bf79-93e920db587f
                © The Author(s) 2023

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 15 February 2023
                : 11 March 2023
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100000026, National Institute on Drug Abuse;
                Award ID: R01DA051849
                Award ID: R01DA051849
                Award ID: R01DA051849
                Award ID: R01DA051849
                Award ID: R01DA051849
                Award ID: R01DA051849
                Award ID: R01DA051849
                Funded by: FundRef http://dx.doi.org/10.13039/100000060, National Institute of Allergy and Infectious Diseases;
                Award ID: P30AI042853
                Categories
                Study Protocol
                Custom metadata
                © The Author(s) 2023

                Public health
                hiv infections,opioid-related disorders,substance-related disorders,pre-exposure prophylaxis,needle-exchange programs,substance use, intravenous,motivational interviewing,self efficacy,patient navigation,social cognitive theory

                Comments

                Comment on this article